Ad
related to: dana farber lynch syndrome center
Search results
Results From The WOW.Com Content Network
Hereditary nonpolyposis colorectal cancer (HNPCC) is a hereditary predisposition to colon cancer.. HNPCC includes (and was once synonymous with) [1] Lynch syndrome, an autosomal dominant genetic condition that is associated with a high risk of colon cancer, endometrial cancer (second most common), ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin. [2]
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts.Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
CRC diagnosed in two or more first-degree or second-degree relatives with Lynch syndrome-associated tumors, regardless of age. [ 5 ] The Revised Bethesda Guidelines have been reported as being more sensitive than the Amsterdam II Criteria in detecting individuals and families at risk of Lynch syndrome.
Under the name constitutional mismatch repair-deficiency (CMMR-D), it has been mapped to MLH1, MSH2, MSH6 or PMS2. [2] Monoallelic mutations of these genes are observed in the condition known as Lynch syndrome or hereditary nonpolyposis colorectal cancer, while biallelic mutations are observed in CMMR-D. [3] People expressing the HNPCC (which itself is considered autosomal dominant) trait are ...
Griffin completed his residency at Johns Hopkins Hospital, a hematology fellowship at Massachusetts General Hospital, and a medical oncology fellowship at Dana–Farber Cancer Institute. [3] He is on the scientific advisory boards of Phio Pharmaceuticals, the Georgetown Lombardi Comprehensive Cancer Center, and the Johns Hopkins Cancer Center. [4]
Edward J. Benz Jr. is the former president of Dana–Farber Cancer Institute in Boston, Massachusetts., [1] and the Richard and Susan Smith Professor of Medicine [2] as well as a professor of genetics at Harvard Medical School. [3] He was named to the presidency of Dana-Farber in 2000, succeeding David G. Nathan. [4]
Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School.D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility.
Mary-Ellen Taplin (born 1960), is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area. Taplin is Institute Physician and Director of Clinical Research for the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute and at the Brigham and Women's ...